back to cluster viewer
cluster path 10111110111110
187 words, 5,471 tokens
freq alpha suffix
Words in frequency order
1 | incremental | 3,777
|
2 | 95th | 353
|
3 | 90th | 283
|
4 | 75th | 264
|
5 | 50th | 115
|
6 | 85th | 107
|
7 | 99th | 105
|
8 | 97th | 27
|
9 | 80th | 25
|
10 | ≥95th | 23
|
11 | 98th | 21
|
12 | ≥85th | 18
|
13 | 97.5th | 17
|
14 | 2.5th | 15
|
15 | =95th | 11
|
16 | or=cin2 | 10
|
17 | =85th | 9
|
18 | breakeven | 8
|
19 | exorbitant | 8
|
20 | 5th-95th | 7
|
21 | ≥99th | 7
|
22 | 65th | 5
|
23 | 8-km | 5
|
24 | 93rd | 5
|
25 | 94th | 5
|
26 | drug-acquisition | 5
|
27 | ≥75th | 5
|
28 | 85th-94th | 4
|
29 | =90th | 4
|
30 | event-year | 4
|
31 | muta-pi | 4
|
32 | or=99th | 4
|
33 | per-unit | 4
|
34 | planned-afl | 4
|
35 | ≥98th | 4
|
36 | /=75th | 3
|
37 | 130-mg/dl | 3
|
38 | 2.5-97.5th | 3
|
39 | 350th | 3
|
40 | 84th | 3
|
41 | 91st | 3
|
42 | per-procedure | 3
|
43 | seventy-fifth | 3
|
44 | sre-related | 3
|
45 | uv-tamxv | 3
|
46 | /=1-point | 2
|
47 | /=2-point | 2
|
48 | 0.67-sd | 2
|
49 | 50th-75th | 2
|
50 | 63rd | 2
|
51 | 85th-95th | 2
|
52 | 89th | 2
|
53 | 90th-95th | 2
|
54 | 95-99th | 2
|
55 | 99.85th | 2
|
56 | =10th | 2
|
57 | =99th | 2
|
58 | erosion-remineralization | 2
|
59 | fa-total | 2
|
60 | fiftieth | 2
|
61 | gbg-response | 2
|
62 | height-specific | 2
|
63 | lhw-naoh | 2
|
64 | mid-sinus | 2
|
65 | non-glycemic | 2
|
66 | or=48-week | 2
|
67 | or=95th | 2
|
68 | vacancy-ordered | 2
|
69 | weight-for-corrected-age | 2
|
70 | work-to-work | 2
|
71 | δreal | 2
|
72 | ≤20th | 2
|
73 | /=10th | 1
|
74 | /=4-point | 1
|
75 | /=85th | 1
|
76 | /=95th | 1
|
77 | 0.5th | 1
|
78 | 1-mv | 1
|
79 | 10'h | 1
|
80 | 11th-94th | 1
|
81 | 190th | 1
|
82 | 2.3rd | 1
|
83 | 3,6-c | 1
|
84 | 3-cm-long | 1
|
85 | 4,000g | 1
|
86 | 4-disc | 1
|
87 | 48.5-57.0 | 1
|
88 | 5-10th | 1
|
89 | 50th-95th | 1
|
90 | 54.3-54.9 | 1
|
91 | 59th | 1
|
92 | 62nd | 1
|
93 | 65.0/75th | 1
|
94 | 68th | 1
|
95 | 74,000-fold | 1
|
96 | 75th-95th | 1
|
97 | 75th-97th | 1
|
98 | 75th:25th | 1
|
99 | 8-county | 1
|
100 | 80th/20th | 1
|
101 | 85-min | 1
|
102 | 88th | 1
|
103 | 90.8th | 1
|
104 | 95th-98th | 1
|
105 | 97,5th | 1
|
106 | 97·5th | 1
|
107 | 99.6th | 1
|
108 | 99.912th | 1
|
109 | =25th | 1
|
110 | age-regressed | 1
|
111 | antincrementar | 1
|
112 | apicoanterior | 1
|
113 | apparatus-based | 1
|
114 | base-stacking-induced | 1
|
115 | before-shift | 1
|
116 | bmi-for-age-sex | 1
|
117 | cefazolin-associated | 1
|
118 | clinical-and | 1
|
119 | cluster-to-person | 1
|
120 | critic-not | 1
|
121 | design-weighted | 1
|
122 | dosage-adjustment | 1
|
123 | echofree | 1
|
124 | echopoor | 1
|
125 | effectiveness/lower | 1
|
126 | epsi | 1
|
127 | evaluation.a | 1
|
128 | exploratory-type | 1
|
129 | force-balanced | 1
|
130 | health-treatment | 1
|
131 | high-international | 1
|
132 | higher/equivalent | 1
|
133 | hour-by-hour | 1
|
134 | hypervitaminotic | 1
|
135 | icf-relevant | 1
|
136 | less-precise | 1
|
137 | levelized | 1
|
138 | lpv-tamxv | 1
|
139 | mask+extra | 1
|
140 | mid-quartile | 1
|
141 | misimprinting | 1
|
142 | nahco3-induced | 1
|
143 | net/no | 1
|
144 | nhi-were | 1
|
145 | observaion | 1
|
146 | or=0-point | 1
|
147 | or=1-log | 1
|
148 | or=1-point | 1
|
149 | or=2-point | 1
|
150 | or=3-point | 1
|
151 | or=75th | 1
|
152 | or=85th | 1
|
153 | or=90th | 1
|
154 | pec-q | 1
|
155 | percentile/75th | 1
|
156 | pharmaka | 1
|
157 | population-referenced | 1
|
158 | progressive-resistive | 1
|
159 | rank-normalized | 1
|
160 | rear-wheel | 1
|
161 | relief-consistently | 1
|
162 | schematize | 1
|
163 | sc₅₀ | 1
|
164 | sex/age/height | 1
|
165 | skin-necrosis | 1
|
166 | skinfold-for-age | 1
|
167 | ssi-related | 1
|
168 | strategy-generating | 1
|
169 | submicro-size | 1
|
170 | tbbmc-for-age | 1
|
171 | translation-function | 1
|
172 | transport/hotels | 1
|
173 | trillion-dollar | 1
|
174 | upsampled | 1
|
175 | urban/suburban | 1
|
176 | uv-wavelength | 1
|
177 | volume-by-age | 1
|
178 | weight-for-height/length | 1
|
179 | β-frequency | 1
|
180 | €17.8 | 1
|
181 | ∼18-mb | 1
|
182 | ∼25-mb | 1
|
183 | ≤50th | 1
|
184 | ≤5th | 1
|
185 | ≤95th | 1
|
186 | ⩾85th | 1
|
187 | 85th | 1
|
Words in alphabetical order
1 | /=1-point | 2
|
2 | /=10th | 1
|
3 | /=2-point | 2
|
4 | /=4-point | 1
|
5 | /=75th | 3
|
6 | /=85th | 1
|
7 | /=95th | 1
|
8 | 0.5th | 1
|
9 | 0.67-sd | 2
|
10 | 1-mv | 1
|
11 | 10'h | 1
|
12 | 11th-94th | 1
|
13 | 130-mg/dl | 3
|
14 | 190th | 1
|
15 | 2.3rd | 1
|
16 | 2.5-97.5th | 3
|
17 | 2.5th | 15
|
18 | 3,6-c | 1
|
19 | 3-cm-long | 1
|
20 | 350th | 3
|
21 | 4,000g | 1
|
22 | 4-disc | 1
|
23 | 48.5-57.0 | 1
|
24 | 5-10th | 1
|
25 | 50th | 115
|
26 | 50th-75th | 2
|
27 | 50th-95th | 1
|
28 | 54.3-54.9 | 1
|
29 | 59th | 1
|
30 | 5th-95th | 7
|
31 | 62nd | 1
|
32 | 63rd | 2
|
33 | 65.0/75th | 1
|
34 | 65th | 5
|
35 | 68th | 1
|
36 | 74,000-fold | 1
|
37 | 75th | 264
|
38 | 75th-95th | 1
|
39 | 75th-97th | 1
|
40 | 75th:25th | 1
|
41 | 8-county | 1
|
42 | 8-km | 5
|
43 | 80th | 25
|
44 | 80th/20th | 1
|
45 | 84th | 3
|
46 | 85-min | 1
|
47 | 85th | 107
|
48 | 85th-94th | 4
|
49 | 85th-95th | 2
|
50 | 88th | 1
|
51 | 89th | 2
|
52 | 90.8th | 1
|
53 | 90th | 283
|
54 | 90th-95th | 2
|
55 | 91st | 3
|
56 | 93rd | 5
|
57 | 94th | 5
|
58 | 95-99th | 2
|
59 | 95th | 353
|
60 | 95th-98th | 1
|
61 | 97,5th | 1
|
62 | 97.5th | 17
|
63 | 97th | 27
|
64 | 97·5th | 1
|
65 | 98th | 21
|
66 | 99.6th | 1
|
67 | 99.85th | 2
|
68 | 99.912th | 1
|
69 | 99th | 105
|
70 | =10th | 2
|
71 | =25th | 1
|
72 | =85th | 9
|
73 | =90th | 4
|
74 | =95th | 11
|
75 | =99th | 2
|
76 | age-regressed | 1
|
77 | antincrementar | 1
|
78 | apicoanterior | 1
|
79 | apparatus-based | 1
|
80 | base-stacking-induced | 1
|
81 | before-shift | 1
|
82 | bmi-for-age-sex | 1
|
83 | breakeven | 8
|
84 | cefazolin-associated | 1
|
85 | clinical-and | 1
|
86 | cluster-to-person | 1
|
87 | critic-not | 1
|
88 | design-weighted | 1
|
89 | dosage-adjustment | 1
|
90 | drug-acquisition | 5
|
91 | echofree | 1
|
92 | echopoor | 1
|
93 | effectiveness/lower | 1
|
94 | epsi | 1
|
95 | erosion-remineralization | 2
|
96 | evaluation.a | 1
|
97 | event-year | 4
|
98 | exorbitant | 8
|
99 | exploratory-type | 1
|
100 | fa-total | 2
|
101 | fiftieth | 2
|
102 | force-balanced | 1
|
103 | gbg-response | 2
|
104 | health-treatment | 1
|
105 | height-specific | 2
|
106 | high-international | 1
|
107 | higher/equivalent | 1
|
108 | hour-by-hour | 1
|
109 | hypervitaminotic | 1
|
110 | icf-relevant | 1
|
111 | incremental | 3,777
|
112 | less-precise | 1
|
113 | levelized | 1
|
114 | lhw-naoh | 2
|
115 | lpv-tamxv | 1
|
116 | mask+extra | 1
|
117 | mid-quartile | 1
|
118 | mid-sinus | 2
|
119 | misimprinting | 1
|
120 | muta-pi | 4
|
121 | nahco3-induced | 1
|
122 | net/no | 1
|
123 | nhi-were | 1
|
124 | non-glycemic | 2
|
125 | observaion | 1
|
126 | or=0-point | 1
|
127 | or=1-log | 1
|
128 | or=1-point | 1
|
129 | or=2-point | 1
|
130 | or=3-point | 1
|
131 | or=48-week | 2
|
132 | or=75th | 1
|
133 | or=85th | 1
|
134 | or=90th | 1
|
135 | or=95th | 2
|
136 | or=99th | 4
|
137 | or=cin2 | 10
|
138 | pec-q | 1
|
139 | per-procedure | 3
|
140 | per-unit | 4
|
141 | percentile/75th | 1
|
142 | pharmaka | 1
|
143 | planned-afl | 4
|
144 | population-referenced | 1
|
145 | progressive-resistive | 1
|
146 | rank-normalized | 1
|
147 | rear-wheel | 1
|
148 | relief-consistently | 1
|
149 | schematize | 1
|
150 | sc₅₀ | 1
|
151 | seventy-fifth | 3
|
152 | sex/age/height | 1
|
153 | skin-necrosis | 1
|
154 | skinfold-for-age | 1
|
155 | sre-related | 3
|
156 | ssi-related | 1
|
157 | strategy-generating | 1
|
158 | submicro-size | 1
|
159 | tbbmc-for-age | 1
|
160 | translation-function | 1
|
161 | transport/hotels | 1
|
162 | trillion-dollar | 1
|
163 | upsampled | 1
|
164 | urban/suburban | 1
|
165 | uv-tamxv | 3
|
166 | uv-wavelength | 1
|
167 | vacancy-ordered | 2
|
168 | volume-by-age | 1
|
169 | weight-for-corrected-age | 2
|
170 | weight-for-height/length | 1
|
171 | work-to-work | 2
|
172 | β-frequency | 1
|
173 | δreal | 2
|
174 | €17.8 | 1
|
175 | ∼18-mb | 1
|
176 | ∼25-mb | 1
|
177 | ≤20th | 2
|
178 | ≤50th | 1
|
179 | ≤5th | 1
|
180 | ≤95th | 1
|
181 | ≥75th | 5
|
182 | ≥85th | 18
|
183 | ≥95th | 23
|
184 | ≥98th | 4
|
185 | ≥99th | 7
|
186 | ⩾85th | 1
|
187 | 85th | 1
|
Words in suffix order
1 | 48.5-57.0 | 1
|
2 | or=cin2 | 10
|
3 | €17.8 | 1
|
4 | 54.3-54.9 | 1
|
5 | evaluation.a | 1
|
6 | pharmaka | 1
|
7 | mask+extra | 1
|
8 | ∼25-mb | 1
|
9 | ∼18-mb | 1
|
10 | 3,6-c | 1
|
11 | height-specific | 2
|
12 | non-glycemic | 2
|
13 | hypervitaminotic | 1
|
14 | 4-disc | 1
|
15 | force-balanced | 1
|
16 | population-referenced | 1
|
17 | nahco3-induced | 1
|
18 | base-stacking-induced | 1
|
19 | upsampled | 1
|
20 | vacancy-ordered | 2
|
21 | apparatus-based | 1
|
22 | age-regressed | 1
|
23 | cefazolin-associated | 1
|
24 | sre-related | 3
|
25 | ssi-related | 1
|
26 | design-weighted | 1
|
27 | rank-normalized | 1
|
28 | levelized | 1
|
29 | 74,000-fold | 1
|
30 | 62nd | 1
|
31 | clinical-and | 1
|
32 | 2.3rd | 1
|
33 | 63rd | 2
|
34 | 93rd | 5
|
35 | 0.67-sd | 2
|
36 | echofree | 1
|
37 | weight-for-corrected-age | 2
|
38 | tbbmc-for-age | 1
|
39 | skinfold-for-age | 1
|
40 | volume-by-age | 1
|
41 | mid-quartile | 1
|
42 | exploratory-type | 1
|
43 | nhi-were | 1
|
44 | per-procedure | 3
|
45 | less-precise | 1
|
46 | gbg-response | 2
|
47 | progressive-resistive | 1
|
48 | submicro-size | 1
|
49 | schematize | 1
|
50 | 4,000g | 1
|
51 | strategy-generating | 1
|
52 | misimprinting | 1
|
53 | 3-cm-long | 1
|
54 | or=1-log | 1
|
55 | 10'h | 1
|
56 | lhw-naoh | 2
|
57 | 5-10th | 1
|
58 | =10th | 2
|
59 | /=10th | 1
|
60 | 80th/20th | 1
|
61 | ≤20th | 2
|
62 | 50th | 115
|
63 | 350th | 3
|
64 | ≤50th | 1
|
65 | 80th | 25
|
66 | 90th | 283
|
67 | 190th | 1
|
68 | =90th | 4
|
69 | or=90th | 1
|
70 | 99.912th | 1
|
71 | 84th | 3
|
72 | 94th | 5
|
73 | 11th-94th | 1
|
74 | 85th-94th | 4
|
75 | 97,5th | 1
|
76 | 0.5th | 1
|
77 | 2.5th | 15
|
78 | 97.5th | 17
|
79 | 2.5-97.5th | 3
|
80 | 75th:25th | 1
|
81 | =25th | 1
|
82 | 65th | 5
|
83 | 75th | 264
|
84 | 50th-75th | 2
|
85 | 65.0/75th | 1
|
86 | percentile/75th | 1
|
87 | /=75th | 3
|
88 | or=75th | 1
|
89 | ≥75th | 5
|
90 | 85th | 107
|
91 | 99.85th | 2
|
92 | =85th | 9
|
93 | /=85th | 1
|
94 | or=85th | 1
|
95 | ≥85th | 18
|
96 | 85th | 1
|
97 | ⩾85th | 1
|
98 | 95th | 353
|
99 | 50th-95th | 1
|
100 | 90th-95th | 2
|
101 | 5th-95th | 7
|
102 | 75th-95th | 1
|
103 | 85th-95th | 2
|
104 | =95th | 11
|
105 | /=95th | 1
|
106 | or=95th | 2
|
107 | ≤95th | 1
|
108 | ≥95th | 23
|
109 | ≤5th | 1
|
110 | 97·5th | 1
|
111 | 99.6th | 1
|
112 | 97th | 27
|
113 | 75th-97th | 1
|
114 | 90.8th | 1
|
115 | 68th | 1
|
116 | 88th | 1
|
117 | 98th | 21
|
118 | 95th-98th | 1
|
119 | ≥98th | 4
|
120 | 59th | 1
|
121 | 89th | 2
|
122 | 99th | 105
|
123 | 95-99th | 2
|
124 | =99th | 2
|
125 | or=99th | 4
|
126 | ≥99th | 7
|
127 | fiftieth | 2
|
128 | seventy-fifth | 3
|
129 | weight-for-height/length | 1
|
130 | uv-wavelength | 1
|
131 | muta-pi | 4
|
132 | epsi | 1
|
133 | or=48-week | 2
|
134 | work-to-work | 2
|
135 | δreal | 2
|
136 | high-international | 1
|
137 | incremental | 3,777
|
138 | fa-total | 2
|
139 | 130-mg/dl | 3
|
140 | rear-wheel | 1
|
141 | planned-afl | 4
|
142 | 8-km | 5
|
143 | urban/suburban | 1
|
144 | breakeven | 8
|
145 | 85-min | 1
|
146 | observaion | 1
|
147 | erosion-remineralization | 2
|
148 | translation-function | 1
|
149 | drug-acquisition | 5
|
150 | cluster-to-person | 1
|
151 | net/no | 1
|
152 | pec-q | 1
|
153 | event-year | 4
|
154 | trillion-dollar | 1
|
155 | antincrementar | 1
|
156 | effectiveness/lower | 1
|
157 | apicoanterior | 1
|
158 | echopoor | 1
|
159 | hour-by-hour | 1
|
160 | skin-necrosis | 1
|
161 | transport/hotels | 1
|
162 | mid-sinus | 2
|
163 | before-shift | 1
|
164 | sex/age/height | 1
|
165 | per-unit | 4
|
166 | exorbitant | 8
|
167 | icf-relevant | 1
|
168 | higher/equivalent | 1
|
169 | health-treatment | 1
|
170 | dosage-adjustment | 1
|
171 | or=0-point | 1
|
172 | /=1-point | 2
|
173 | or=1-point | 1
|
174 | /=2-point | 2
|
175 | or=2-point | 1
|
176 | or=3-point | 1
|
177 | /=4-point | 1
|
178 | critic-not | 1
|
179 | 91st | 3
|
180 | 1-mv | 1
|
181 | lpv-tamxv | 1
|
182 | uv-tamxv | 3
|
183 | bmi-for-age-sex | 1
|
184 | β-frequency | 1
|
185 | relief-consistently | 1
|
186 | 8-county | 1
|
187 | sc₅₀ | 1
|